BOSTON and NOIDA, India, Feb. 15, 2024 /CNW/ -- Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that ...

Boston [US]/ Noida (Uttar Pradesh) [India], February 15: Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties ...

BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a ...

is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site. An ...

BOSTON, June 10, 2025 /PRNewswire/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a ...

Noida (Uttar Pradesh) [India], October 25 (ANI/PRNewswire): Curadev's emphasis on education stems from its transformational effects on the individual and society at large. While education is of ...

Pride India Awards Special Edition 2025 Indian Icon of Real Estate Excellence - NBR Group:From Foundations to Futures, Introducing NBR Soul of the Seasons ...

Boston [US]/Noida (Uttar Pradesh) [India], February 29: Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs targeting the immune ...

LONDON, May 8, 2019 /PRNewswire/ -- Curadev today announced it has licensed its novel lead small molecule Stimulator of Interferon Genes (STING) agonist (referred to by Curadev as CRD5500) and ...